Navigation Links
Jefferson urologists studying regenerated neo-bladder to help spinal cord injury patients

Urologists at Thomas Jefferson University Hospital are studying whether a neo-bladder construct grown from a patients own cells can improve bladder function for adult spinal cord injury patients.

Jefferson is only one of six sites in the U.S. enrolling participants in this clinical trial for the lab-grown neo-bladder construct that will involve a total of 10 patients.

Its never been done in adults before, said primary investigator Patrick Shenot, M.D., instructor in Urology, Jefferson Medical College of Thomas Jefferson University, noting that a similar study is being conducted with children with spina bifida.

The neo-bladder constructs are being developed by Tengion, Inc. in their pilot manufacturing facility.

Each neo-bladder construct consists of a biodegradable scaffold seeded with urothelial and smooth muscle cells cultured in Tengions facility from the patients own bladder cells.

To participate in the study, a patient must be 18 to 65 years of age, have had a spinal cord injury for more than a year and diagnosed with a neurogenic bladder that is not adequately responding to medical therapy.

The urologist first performs a biopsy on the patient to retrieve the cells. The cells are then sent to Tengions manufacturing facility where they are grown in culture and then seeded onto a biodegradable scaffold in the shape of a bladder.

Then, the patient returns to hospital and the urologist will implant the neo-bladder construct in a procedure known as augmentation cystoplasty or bladder augmentation.

The neo-bladder is expected to continue to regenerate within the patient, using the bodys inherent regenerative capabilities, and if successful may result in improved bladder function, Dr. Shenot noted.

The field of regenerative medicine is anticipated to be an area of intense interest and expansion in the coming years, said Dr. Shenot.

While this first trial in adults is for patients with bladder control problems due to spinal cord injury, the possibilities for expansion into oncology related areas are promising, he said.


Contact: Jeff Baxt
Thomas Jefferson University

Related biology news :

1. Jefferson Virologists Coax HIV Out of Hiding
2. Jefferson researchers find nanoparticle shows promise in reducing radiation side effects
3. Jefferson biologist coaxing human embryonic stem cells to make dopamine with simpler, faster method
4. Jefferson scientists identify gene defect leading to abnormal skin development and cancer
5. Jefferson researchers building a better rabies vaccine
6. Jefferson scientists identify gene mutation potentially involved in breast cancer initiation
7. Immune cell communication key to hunting viruses, Jefferson immunologists show
8. Jefferson researchers uncover new way nature turns genes on and off
9. Jefferson scientists find aging gene also protects against prostate cancer development
10. Jefferson scientists find high glucose before surgery raises risk of dangerous complications
11. Jefferson researchers discovery may change thinking on how viruses invade the brain
Post Your Comments:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... June 2, 2016 The Department of ... awarded the 44 million US Dollar project, for the ... Plates including Personalization, Enrolment, and IT Infrastructure , ... the production and implementation of Identity Management Solutions. Numerous renowned ... Decatur was selected for the most ...
(Date:5/20/2016)... , May 20, 2016  VoiceIt is excited ... with VoicePass. By working together, VoiceIt ...  Because VoiceIt and VoicePass take slightly different approaches ... increases both security and usability. ... about this new partnership. "This marketing ...
Breaking Biology News(10 mins):
(Date:6/24/2016)... 24, 2016 Epic Sciences unveiled a ... susceptible to PARP inhibitors by targeting homologous recombination ... The new test has already been incorporated into ... cancer types. Over 230 clinical trials ... pathways, including PARP, ATM, ATR, DNA-PK and WEE-1. ...
(Date:6/24/2016)... ... 2016 , ... Researchers at the Universita Politecnica delle Marche in Ancona combed ... pleural mesothelioma. Their findings are the subject of a new article on the Surviving ... signposts in the blood, lung fluid or tissue of mesothelioma patients that can help ...
(Date:6/23/2016)... ... June 23, 2016 , ... UAS LifeSciences, one ... of their brand, UP4™ Probiotics, into Target stores nationwide. The company, which has ... add Target to its list of well-respected retailers. This list includes such fine ...
(Date:6/23/2016)... /PRNewswire/ - FACIT has announced the creation of ... company, Propellon Therapeutics Inc. ("Propellon" or "the Company"), ... portfolio of first-in-class WDR5 inhibitors for the treatment ... represent an exciting class of therapies, possessing the ... cancer patients. Substantial advances have been achieved with ...
Breaking Biology Technology: